16 results on '"Shemshedini, Lirim"'
Search Results
2. Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer.
- Author
-
Han, Zhengyang, Rimal, Ujjwal, Khatiwada, Prabesh, Brandman, Jacob, Zhou, Jun, Hussain, Muhammad, Viola, Ronald E, and Shemshedini, Lirim
- Subjects
CASTRATION-resistant prostate cancer ,PEPTIDES ,THERAPEUTICS ,PROSTATE cancer ,DRUG resistance ,DRUG therapy ,ANDROGEN receptors - Abstract
Prostate cancer starts as a treatable hormone-dependent disease, but often ends in a drug-resistant form called castration-resistant prostate cancer (CRPC). Despite the development of the antiandrogens enzalutamide and abiraterone for CRPC, which target the androgen receptor (AR), drug resistance usually develops within 6 months and metastatic CRPC (mCRPC) leads to lethality. EZH2, found with SUZ12, EED, and RbAP48 in Polycomb repressive complex 2 (PRC2), has emerged as an alternative target for the treatment of deadly mCRPC. Unfortunately, drugs targeting EZH2 have shown limited efficacy in mCRPC. To address these failures, we have developed novel, dual-acting peptide inhibitors of PRC2 that uniquely target the SUZ12 protein component, resulting in the inhibition of both PRC2 canonical and noncanonical functions in prostate cancer. These peptides were found to inhibit not only the EZH2 methylation activity, but also block its positive effect on AR gene expression in prostate cancer cells. Since the peptide effect on AR levels is transcriptional, the inhibitory peptides can block the expression of both full-length AR and its splicing variants including AR-V7, which plays a significant role in the development of drug resistance. This dual-mode action provides the peptides with the capability to kill enzalutamide-resistant CRPC cells. These peptides are also more cytotoxic to prostate cancer cells than the combination of enzalutamide and an EZH2 inhibitory drug, which was recently suggested to be an effective treatment of mCRPC disease. Our data show that such a dual-acting therapeutic approach can be more effective than the existing front-line drug therapies for treating deadly mCRPC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer.
- Author
-
Han, Zhengyang, Rimal, Ujjwal, Khatiwada, Prabesh, Brandman, Jacob, Zhou, Jun, Hussain, Muhammad, Viola, Ronald E, and Shemshedini, Lirim
- Abstract
Prostate cancer starts as a treatable hormone-dependent disease, but often ends in a drug-resistant form called castration-resistant prostate cancer (CRPC). Despite the development of the antiandrogens enzalutamide and abiraterone for CRPC, which target the androgen receptor (AR), drug resistance usually develops within 6 months and metastatic CRPC (mCRPC) leads to lethality. EZH2, found with SUZ12, EED, and RbAP48 in Polycomb repressive complex 2 (PRC2), has emerged as an alternative target for the treatment of deadly mCRPC. Unfortunately, drugs targeting EZH2 have shown limited efficacy in mCRPC. To address these failures, we have developed novel, dual-acting peptide inhibitors of PRC2 that uniquely target the SUZ12 protein component, resulting in the inhibition of both PRC2 canonical and noncanonical functions in prostate cancer. These peptides were found to inhibit not only the EZH2 methylation activity, but also block its positive effect on AR gene expression in prostate cancer cells. Since the peptide effect on AR levels is transcriptional, the inhibitory peptides can block the expression of both full-length AR and its splicing variants including AR-V7, which plays a significant role in the development of drug resistance. This dual-mode action provides the peptides with the capability to kill enzalutamide-resistant CRPC cells. These peptides are also more cytotoxic to prostate cancer cells than the combination of enzalutamide and an EZH2 inhibitory drug, which was recently suggested to be an effective treatment of mCRPC disease. Our data show that such a dual-acting therapeutic approach can be more effective than the existing front-line drug therapies for treating deadly mCRPC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Resistance to Juvenile Hormone and an Insect Growth Regulator in Drosophila is Associated with an Altered Cytosolic Juvenile Hormone-Binding Protein
- Author
-
Shemshedini, Lirim and Wilson, Thomas G.
- Published
- 1990
5. Makorin RING finger protein 1 (MKRN1) has negative and positive effects on RNA polymerase II-dependent transcription
- Author
-
Omwancha, Josephat, Zhou, Xiao-Feng, Chen, Shao-Yong, Baslan, Timour, Fisher, Christopher J., Zheng, Zhe, Cai, Changmeng, and Shemshedini, Lirim
- Published
- 2006
- Full Text
- View/download PDF
6. c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription
- Author
-
Bubulya, Athanasios, Zhou, Xiao-Feng, Shen, Xi-Qiang, Fisher, Christopher J., and Shemshedini, Lirim
- Published
- 2000
- Full Text
- View/download PDF
7. Ligand-free RAR can interact with the RNA polymerase II subunit hsRPB7 and repress transcription
- Author
-
Shen, Xi-Qiang, Bubulya, Athanasios, Zhou, Xiao-Feng, Khazak, Vladimir, Golemis, Erica A., and Shemshedini, Lirim
- Published
- 1999
- Full Text
- View/download PDF
8. c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation
- Author
-
Tillman, Karl, Oberfield, Jennifer L., Shen, Xi-Qiang, Bubulya, Athanasios, and Shemshedini, Lirim
- Published
- 1998
- Full Text
- View/download PDF
9. Identification of domains of c-Jun mediating androgen receptor transactivation
- Author
-
Wise, Scott C, Burmeister, Lori A, Zhou, Xiao-feng, Bubulya, Athanasios, Oberfield, Jennifer L, Birrer, Michael J, and Shemshedini, Lirim
- Published
- 1998
- Full Text
- View/download PDF
10. Androgen up-regulation of Twist1 gene expression is mediated by ETV1.
- Author
-
Khatiwada, Prabesh, Kannan, Archana, Malla, Mamata, Dreier, Megan, and Shemshedini, Lirim
- Subjects
GENE expression ,ANDROGENS ,ANDROGEN receptors ,BINDING sites ,TRANSCRIPTION factors ,PROSTATE cancer - Abstract
Twist1, a basic helix-loop-helix transcription factor that regulates a number of genes involved in epithelial-to-mesenchymal transition (EMT), is upregulated in prostate cancer. Androgen regulation of Twist1 has been reported in a previous study. However, the mechanism of androgen regulation of the Twist1 gene is not understood because the Twist1 promoter lacks androgen receptor (AR)-responsive elements. Previous studies have shown that the Twist1 promoter has putative binding sites for PEA3 subfamily of ETS transcription factors. Our lab has previously identified Ets Variant 1 (ETV1), a member of the PEA3 subfamily, as a novel androgen-regulated gene that is involved in prostate cancer cell invasion through unknown mechanism. In view of these data, we hypothesized that androgen-activated AR upregulates Twist1 gene expression via ETV1. Our data confirmed the published work that androgen positively regulates Twist1 gene expression and further showed that this positive effect was directed at the Twist1 promoter. The positive effect of androgen on Twist1 gene expression was abrogated upon disruption of AR expression by siRNA or of AR activity by Casodex. More importantly, our data show that disruption of ETV1 leads to significant decrease in both androgen-mediated upregulation as well as basal level of Twist1, which we are able to rescue upon re-expression of ETV1. Indeed, we are able to show that ETV1 mediates the androgen upregulation of Twist1 by acting on the proximal region of Twist1 promoter. Additionally, our data show that Twist1 regulates prostate cancer cell invasion and EMT, providing a possible mechanism by which ETV1 mediates prostate cancer cell invasion. In conclusion, in this study we report Twist1 as an indirect target of AR and androgen regulation through ETV1. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Peptide B targets soluble guanylyl cyclase α1 and kills prostate cancer cells.
- Author
-
Zhou, Jun, Gao, Shuai, Hsieh, Chen-Lin, Malla, Mamata, and Shemshedini, Lirim
- Subjects
PEPTIDES ,NEOVASCULARIZATION ,PROSTATE cancer ,NITRIC oxide ,REACTIVE oxygen species ,ANTINEOPLASTIC agents ,APOPTOSIS - Abstract
Among androgen-regulated genes, soluble guanylyl cyclase α1 (sGCα1) is significant in promoting the survival and growth of prostate cancer cells and does so independent of nitric oxide (NO) signaling. Peptides were designed targeting sGCα1 to block its pro-cancer functions and one peptide is discussed here. Peptide B-8R killed both androgen-dependent and androgen-independent prostate cancer cells that expressed sGCα1, but not cells that do not express this gene. Peptide B-8R induced apoptosis of prostate cancer cells. Importantly, Peptide B-8R does not affect nor its cytotoxicity depend on NO signaling, despite the fact that it associates with sGCα1, which dimerizes with sGCβ1 to form the sGC enzyme. Just as with a previously studied Peptide A-8R, Peptide B-8R induced elevated levels of reactive oxygen species (ROS) in prostate cancer cells, but using a ROS-sequestering agent showed that ROS was not responsible the cytotoxic activity of Peptide B-8R. Interestingly, Peptide B-8R induced elevated levels of p53 and phosphorylated p38, but neither of these changes is the cause of the peptide’s cytotoxicity. Additional drugs were used to alter levels of iron levels in cells and these studies showed that Peptide B-8R activity does not depend on Ferroptosis. Thus, future work will be directed at defining the mechanism of cytotoxic action of Peptide B-8R against prostate cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells.
- Author
-
Dayal, Shubham, Jun Zhou, Manivannan, Praveen, Siddiqui, Mohammad Adnan, Ahmad, Omaima Farid, Clark, Matthew, Awadia, Sahezeel, Garcia-Mata, Rafael, Shemshedini, Lirim, and Malathi, Krishnamurthy
- Subjects
CELL migration ,METALLOPROTEINASES ,CANCER cells ,PROSTATE cancer ,ENDORIBONUCLEASES - Abstract
The interferon antiviral pathways and prostate cancer genetics converge on a regulated endoribonuclease, RNase L. Positional cloning and linkage studies mapped Hereditary Prostate Cancer 1 (HPC1) to RNASEL. To date, there is no correlation of viral infections with prostate cancer, suggesting that RNase L may play additional roles in tumor suppression. Here, we demonstrate a role of RNase L as a suppressor of androgen receptor (AR) signaling, cell migration and matrix metalloproteinase activity. Using RNase L mutants, we show that its nucleolytic activity is dispensable for both AR signaling and migration. The most prevalent HPC1-associated mutations in RNase L, R462Q and E265X, enhance AR signaling and cell migration. RNase L negatively regulates cell migration and attachment on various extracellular matrices. We demonstrate that RNase L knockdown cells promote increased cell surface expression of integrin β1 which activates Focal Adhesion Kinase-Sarcoma (FAK-Src) pathway and Ras-related C3 botulinum toxin substrate 1-guanosine triphosphatase (Rac1-GTPase) activity to increase cell migration. Activity of matrix metalloproteinase (MMP)-2 and -9 is significantly increased in cells where RNase L levels are ablated. We show that mutations in RNase L found in HPC patients may promote prostate cancer by increasing expression of AR-responsive genes and cell motility and identify novel roles of RNase L as a prostate cancer susceptibility gene. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Zinc Finger 280B Regulates sGCα1 and p53 in Prostate Cancer Cells.
- Author
-
Gao, Shuai, Hsieh, Chen-Lin, Zhou, Jun, and Shemshedini, Lirim
- Subjects
ZINC-finger proteins ,P53 protein ,PROSTATE cancer ,GENE expression ,GUANYLATE cyclase ,PROTEASOMES ,UBIQUITIN ligases - Abstract
The Zinc Finger (ZNF) 280B protein was identified as an unexpected target of an shRNA designed for sGCα1. Further analysis showed that these two proteins are connected in another way, with 280B up-regulation of sGCα1 expression. Knock-down and over-expression experiments showed that 280B serves pro-growth and pro-survival functions in prostate cancer. Surprisingly however, these pro-cancer functions of 280B are not mediated by sGCα1, which itself has similar functions in prostate cancer, but by down-regulated p53. The p53 protein is a second target of 280B in prostate cancer, but unlike sGCα1, p53 is down-regulated by 280B. 280B induces p53 nuclear export, leading to subsequent proteasomal degradation. The protein responsible for p53 regulation by 280B is Mdm2, the E3 ubiquitin ligase that promotes p53 degradation by inducing its nuclear export. We show here that 280B up-regulates expression of Mdm2 in prostate cancer cells, and this regulation is via the Mdm2 promoter. To demonstrate an in vivo relevance to this interaction, expression studies show that 280B protein levels are up-regulated in prostate cancer and these levels correspond to reduced levels of p53. Thus, by enhancing the expression of Mdm2, the uncharacterized 280B protein provides a novel mechanism of p53 suppression in prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. A Peptide against Soluble Guanylyl Cyclase α1: A New Approach to Treating Prostate Cancer
- Author
-
Gao, Shuai, Hsieh, Chen-Lin, Bhansali, Meenakshi, Kannan, Archana, and Shemshedini, Lirim
- Subjects
GUANYLATE cyclase ,PROSTATE cancer treatment ,PEPTIDES ,ANDROGEN receptors ,GENETIC regulation ,CELLULAR signal transduction ,APOPTOSIS - Abstract
Among the many identified androgen-regulated genes, sGCα1 (soluble guanylyl cyclase α1) appears to play a pivotal role in mediating the pro-cancer effects of androgens and androgen receptor. The classical role for sGCα1 is to heterodimerize with the sGCβ1 subunit, forming sGC, the enzyme that mediates nitric oxide signaling by catalyzing the synthesis of cyclic guanosine monophosphate. Our published data show that sGCα1 can drive prostate cancer cell proliferation independent of hormone and provide cancer cells a pro-survival function, via a novel mechanism for p53 inhibition, both of which are independent of sGCβ1, NO, and cGMP. All of these properties make sGCα1 an important novel target for prostate cancer therapy. Thus, peptides were designed targeting sGCα1 with the aim of disrupting this protein’s pro-cancer activities. One peptide (A-8R) was determined to be strongly cytotoxic to prostate cancer cells, rapidly inducing apoptosis. Cytotoxicity was observed in both hormone-dependent and, significantly, hormone-refractory prostate cancer cells, opening the possibility that this peptide can be used to treat the usually lethal castration-resistant prostate cancer. In mouse xenograft studies, Peptide A-8R was able to stop tumor growth of not only hormone-dependent cells, but most importantly from hormone-independent cells. In addition, the mechanism of Peptide A cytotoxicity is generation of reactive oxygen species, which recently have been recognized as a major mode of action of important cancer drugs. Thus, this paper provides strong evidence that targeting an important AR-regulated gene is a new paradigm for effective prostate cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. SUMO-3 Enhances Androgen Receptor Transcriptional Activity through a Sumoylation-independent Mechanism in Prostate Cancer Cells.
- Author
-
Zhe Zheng, Changmeng Cai, Omwancha, Josephat, Shao-Yong Chen, Baslan, Timour, and Shemshedini, Lirim
- Subjects
- *
PROSTATE diseases , *ANDROGENS , *NUCLEAR receptors (Biochemistry) , *ANDROGEN-binding proteins , *EPITHELIAL cells , *EUKARYOTIC cells , *CELL proliferation - Abstract
Androgens are important for male sexual development, which depend on the cognate receptor, the androgen receptor. The transcriptional activity of the androgen receptor, like other nuclear receptors, is regulated by accessory proteins that can have either positive or negative effects. Through a yeast functional screen, we have identified SUMO-3 as a regulator of androgen receptor activity in prostate cancer cells. SUMO-3 is one of three eukaryotic proteins that become post-translationally conjugated to their target proteins in a manner analogous to the attachment of ubiquitin. In primary prostate epithelial cells, PrEC, and the prostate cancer cells, PC-3, SUMO-3 has a weak negative effect on androgen receptor transcriptional activity. In contrast, SUMO-3 and it close relative SUMO-2 strongly enhance transactivation by endogenous androgen receptor in LNCaP cells. This positive effect is observed in both androgen-dependent and androgen-independent LNCaP cells. Interestingly, SUMO-1, unlike SUMO-3 and SUMO-2, can inhibit, but not stimulate, androgen receptor activity. Mutational analysis of the androgen receptor and SUMO-3 demonstrates that the SUMO-3-positive activity does not depend on either the sumoylation sites of the androgen receptor or the sumoylation function of SUMO-3. Stable overexpression of SUMO-3 in LNCaP cells significantly enhances the androgen-dependent proliferation of these cells. Additionally, siRNA-mediated repression of SUMO-2 significantly inhibits the growth of both androgen-dependent and -independent LNCaP cells. Collectively, these results suggest (i) a novel mechanism for elevating AR activity through the switch of SUMO-3 from a weak negative regulator in normal prostate cells to a strong positive regulator in prostate cancer cells and (ii) a proliferative role for SUMO-3 and SUMO-2 in the growth of prostate cancer cells that is independent of sumoylation of the androgen receptor. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
16. Glycogen Synthase Kinase-3β Is Involved in the Phosphorylation and Suppression of Androgen Receptor Activity.
- Author
-
Salas, Thomas R., Kim, Jeri, Vakar-Lopez, Funda, Sabichi, Anita L., Troncoso, Patricia, Jenster, Guido, Kikuchi, Akira, Shao-Yong Chen, Shemshedini, Lirim, Suraokar, Milind, Logothetis, Christopher J., DiGiovanni, John, Lippman, Scott M., and Menter, David G.
- Subjects
- *
PHOSPHORYLASES , *PROSTATE cancer , *GLYCOGEN , *CANCER , *TUMORS , *LIGAND binding (Biochemistry) , *ANDROGENS - Abstract
Kinases can phosphorylate and regulate androgen receptor activity during prostate cancer progression. In particular, we showed that glycogen synthase kinase-3β phosphorylates the androgen receptor, thereby inhibiting androgen receptor-driven transcription. Conversely, the glycogen synthase kinase-3β inhibitor lithium chloride suppressed the glycogen synthase kinase3β-mediated phosphorylation of the androgen receptor, thereby enabling androgen receptor-driven transcription to occur. The androgen receptor hinge and ligandbinding domains were important for both the phosphorylation and the inhibition of transcriptional activity of the receptor by glycogen synthase kinase-3β. Furthermore, androgen receptor phosphorylation was augmented by LY294002, an indirect inhibitor of protein kinase B/Akt that inhibits glycogen synthase kinase-3β. We also showed that the mutation of various phosphorylation sites on glycogen synthase kinase-3β affected the ability of these mutants to co-distribute with the androgen receptor in the cell nucleus, also that both glycogen synthase kinase-3β and androgen receptor proteins can be found in cell nuclei of prostate cancer tissue samples. Because glycogen synthase kinase-3β activity is suppressed after the enzyme is phosphorylated by protein kinase B/Akt and Akt activity frequently increases during the progression of prostate cancer, nullification of the glycogen synthase kinase-3β-mediated suppression of androgen receptor activity by Akt likely contributes to prostate cancer progression. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.